Guides for diagnostic development

510(k) vs De Novo vs PMA for diagnostic tests

The pathway follows your test's risk and whether a similar test is already on the market. Most moderate-risk tests with a predicate go through a 510(k). A new moderate-risk test with no predicate goes through De Novo. High-risk tests, including most companion diagnostics, need premarket approval (PMA).

At a glance

The three pathways compared

Class II (some Class I)

510(k)

When it fits

A legally marketed predicate exists

What you must show

Substantial equivalence to the predicate

Typical evidence

Analytical validation and method comparison; clinical data sometimes

FDA review goal (MDUFA V)

90 FDA days for 95% of submissions

Class I or II, new type

De Novo

When it fits

No predicate; low to moderate risk manageable by special controls

What you must show

Reasonable assurance of safety and effectiveness, plus proposed special controls

Typical evidence

Analytical validation and usually clinical performance data

FDA review goal (MDUFA V)

150 FDA days for 70% of requests

Class III

PMA

When it fits

High risk, such as most companion diagnostics

What you must show

Reasonable assurance of safety and effectiveness

Typical evidence

Full analytical and clinical studies, manufacturing review, often an inspection

FDA review goal (MDUFA V)

About 285–290 days total time to decision

"FDA days" exclude time the clock is stopped while you answer FDA's questions, so calendar time is longer. MDUFA VI goals start October 2027.

One real example

How the pathways connect

  1. De Novo creates the category. 23andMe's celiac genetic health risk test had no predicate, so it went through De Novo (DEN160026), creating a new Class II regulation, 21 CFR 866.5950, with special controls.
  2. 510(k) follows. Later tests of the same type can use it as a predicate. ResearchDx and Targeted Genomics cleared the GlutenID celiac test by 510(k) (K241456), even though it reports four haplotypes on a different platform. Read the case study.
  3. PMA is for the highest stakes. A test whose result decides whether a patient gets a specific drug, such as an NGS companion diagnostic for a targeted cancer therapy, is usually Class III and needs a PMA.
The practical question is rarely which pathway you prefer. It is whether a close enough predicate exists, and what risk a wrong result carries.

Every pathway

What every submission needs

  • A clear intended use: what is measured, in which specimen, for which patients, and how results are used.
  • Analytical validation: accuracy, precision across lots, operators, instruments and days, detection limits, interference and stability.
  • Clinical evidence matched to the claim: little or none for many 510(k)s, more for De Novo, the most for PMA.
  • Labeling and software documentation, including any bioinformatics pipeline.
  • A quality system for design controls and manufacturing.
Start with a Pre-Submission. A Pre-Sub (Q-Sub) gets FDA's written feedback on your pathway, predicate and study plans before you run the studies; under MDUFA V, FDA aims to respond within 70 calendar days for 90% of requests.

Planning a 510(k), De Novo or PMA submission?

We design and run the validation studies, write the submission and run cleared tests in our CLIA/CAP laboratory.